Data demonstrates a 7-day treatment regimen with the pan-coronavirus protease inhibitor ALG-097558 was well tolerated and does not require ...
With almost 775 million COVID-19 cases reported worldwide and 67% of the global population vaccinated with a complete primary series of a COVID-19 vaccine, the deadly pace of the pandemic has slowed ...
Researchers have described the optimal timing for COVID-19 patients to take the antiviral, Paxlovid, to get the most benefit from the treatment, according to a study published April 16 in eLife.
First patient enrolled in the global, 300-patient, Phase 2 adaptive platform trial arm of RHB-107 (upamostat)1 for early ...
Intranasal administration of neomycin sulfate in murine models shows promise as a prophylactic and therapeutic agent against ...
A fingerful of Neosporin antibiotic swabbed inside your nose might help you fight off a range of invading respiratory viruses ...
The CDC estimates that 7.5 percent of U.S. adults have long COVID symptoms 1. David Cutler, PhD, a professor of economics at Harvard University, estimates in a recent research disclosure that the ...
Patients with inflammatory bowel disease receiving immunosuppressant medication are more likely to receive anti-viral or IV antibody treatment for COVID-19. While inflammatory bowel disease (IBD) ...
Yale researchers say that nasal application of neomycin shows promise in the prevention and treatment of respiratory viral ...
No matter how implausible it is or how weak the evidence for it is, the myth that COVID vaccines cause "turbo cancer" just ...